Seeking Alpha

Arrowhead Research Corporation (ARWR)

  • Thu, Mar. 5, 9:15 AM
  • Thu, Mar. 5, 8:06 AM
    • Arrowhead Research (NASDAQ:ARWR) acquires Novartis' (NYSE:NVS) RNA interference (RNAi) R&D portfolio and associated assets, including certain patents and patent applications, an exclusive license to other patents and patent applications owned or controlled by Novartis, the assignment of a third party license and three preclinical product candidates.
    • Specific assets include multiple patent families covering RNAi-trigger design rules and modifications that fall outside of competitors' patents which provides Arrowhead freedom to operate for any target or indication, the assignment of Novartis' license from Alnylam (NASDAQ:ALNY) that gives Arrowhead access to Alnylam IP, excluding delivery, covering 30 gene targets and three product candidates with varying amounts of preclinical data.
    • Under the terms of the agreement, Arrowhead will pay $10M in cash (includes $7M paid previously) and $25M in ARWR stock within 30 days. Novartis is eligible to receive milestones and single-digit royalties on net sales.
    • Arrowhead will host a conference call this morning at 8:30 am to discuss the deal.
    | 1 Comment
  • Mon, Feb. 9, 4:03 PM
    • Arrowhead Research Corporation (NASDAQ:ARWR): FQ1 EPS of -$0.41 misses by $0.07.
    • Revenue of $0.17M (+325.0% Y/Y)
    • Press Release
  • Mon, Feb. 2, 4:15 PM
    • Arrowhead Research (NASDAQ:ARWR) will report fiscal Q1 results on February 9 after the close. The conference call will begin at 4:30 pm ET.
  • Thu, Jan. 22, 9:15 AM
    | 1 Comment
  • Mon, Jan. 12, 1:27 PM
    • Arrowhead Research (ARWR -25.5%) plummets on more than double normal volume after the company disclosed that the FDA has placed a partial clinical hold on the multiple-dose study evaluating ARC-520 in patients with chronic hepatitis B infection. The company will be able to proceed with the 1 mg/kg dose but not the planned 2 mg/kg and 4 mg/kg parallel doses.
    • The FDA also requested additional information including a final report from the single-dose Phase 2a study in patients who received 1-4 mg/kg ARC-520 and a final report from an ongoing multiple-dose non-clinical study. The agency committed to sending a letter to the firm detailing the issues within 30 days.
    • The company intends to start additional Phase 2b trials in Asia and Europe in the coming weeks.
  • Mon, Jan. 12, 12:46 PM
    | Comment!
  • Mon, Jan. 12, 9:14 AM
    | Comment!
  • Fri, Jan. 2, 8:33 AM
    • Arrowhead Research (NASDAQ:ARWR) is up 5% premarket on higher-than-normal volume. Rumors that Gilead Sciences may be eyeing the company stoked an up move on Tuesday.
    • Previously: Arrowhead up on rumor of Gilead interest (Dec. 30, 2014)
    | 1 Comment
  • Dec. 31, 2014, 9:15 AM
    | Comment!
  • Dec. 30, 2014, 12:48 PM
    | 1 Comment
  • Dec. 30, 2014, 12:26 PM
    • Small cap Arrowhead Research (ARWR +17.5%) is up on 50% higher volume on rumors that Gilead Sciences (GILD -0.9%) may be eyeing the company for its RNA interference-based drugs.
    • Arrowhead has yet to recover from the plunge in October after it reported Phase 2a results for its hepatitis B candidate, ARC-520, that fell short of investors' expectations.
    • Gilead has three drugs in development for the treatment of chronic HBV infection: tenofovir alafanamide, a nucleotide reverse transcriptase inhibitor, GS-4774, a Tarmogen T cell immunity stimulator and GS-9620, a TLR-7 agonist in addition to the commercially available Viread (tenofovir disoproxil fumarate) and Hepsera (adefovir dipivoxil).
    • Previously: Arrowhead explains the ARC-520 data (Oct. 9)
  • Nov. 26, 2014, 7:08 AM
    • Arrwohead Research Corp. (ARWR -5.3%) FY2014 results: Revenues: $175K (-39.7%); R&D Expense: $23.1M (+165.5%); SG&A: $5.9M (+68.6%); Operating Loss: ($53.3M) (-116.7%); Net Loss: ($58.7M) (-85.2%); Loss Per Share: ($1.25) (+3.8%); Quick Assets: $132.5M (+593.7%).
    • No guidance given.
    | Comment!
  • Nov. 25, 2014, 4:26 PM
    • Arrowhead Research Corporation (NASDAQ:ARWR): FY14 EPS of -$1.25 vs. -$1.30 in FY13.
    • Revenue of $175K (-39.7% Y/Y).
    • Press Release
    | Comment!
  • Nov. 18, 2014, 4:14 PM
    • Arrowhead Research (NASDAQ:ARWR) will report fiscal Q4 and full-year results on Tuesday, November 25 after the close. The conference call will begin at 1:30 pm PT/4:30 pm ET.
    • Consensus view is a loss of ($0.24) per share on revenues of $40K.
    | Comment!
  • Oct. 9, 2014, 9:18 AM
    • In an open letter to shareholders, Arrowhead Research (NASDAQ:ARWR) CEO Christopher Anzalone, Ph.D., says the market's reaction to the Phase 2a study of ARC-520 surprised the firm considering the consistent nature of the company's communications on the matter. He believes investors expected something different (obviously) or misunderstood the data.
    • Their goal of a l log (90% knockdown) reduction in HBsAg after a single administration is arbitrary since the degree of knockdown necessary to de-repress the immune system and potentially enable a functional cure is unknown. They chose 1 log based on the scientific literature on the small number of patients on Interferon therapy who achieved a functional cure on the basis of a 1/2 log (70% knockdown) reduction in HBsAg after 12 weeks and a 1 log reduction after 24 weeks. Dr. Anzalone refers to the 1 log goal as "intellectually honest."
    • The Phase 2a trial is a dose-finding study. Management disclosed that the first two dose levels (1 mg/kg, 2 mg/kg) would not meet their knockdown goals in the August 12 earnings call. They are prepared to go up to 4 mg/kg since there is little risk of toxicity based on their unblinded Phase 1 safety data. They have just completed dosing eight patients in the 3 mg/kg cohort and will escalate to 4 mg/kg as the data come in.
    • In an animal study on a hepatitis B-infected chimpanzee, the HBsAg knockdown was 80 - 85% after it received the 3 mg/kg dose.
    • The market appears receptive to Dr. Anzalone's explanation. Shares are up 9% premarket on healthy volume.
Visit Seeking Alpha's
ARWR vs. ETF Alternatives
Company Description
Arrowhead Research Corp is engaged in developing novel drugs to treat intractable diseases by silencing the genes. The Company's drug candidate ARC-520 is designed to treat chronic hepatitis B infection.
Sector: Healthcare
Industry: Biotechnology
Country: United States